Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

TLR polymorphisms and the risk of invasive fungal infections.

Pamer EG.

N Engl J Med. 2008 Oct 23;359(17):1836-8. doi: 10.1056/NEJMe0806412. No abstract available.

2.

Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.

Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, Rodrigues SD, Li S, Hansen JA, Zhao LP, Aderem A, Boeckh M.

N Engl J Med. 2008 Oct 23;359(17):1766-77. doi: 10.1056/NEJMoa0802629.

3.

Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors.

Bailey JR, Brennan TP, O'Connell KA, Siliciano RF, Blankson JN.

J Virol. 2009 Jan;83(1):88-97. doi: 10.1128/JVI.01958-08. Epub 2008 Oct 22.

4.

HIV dynamics in seminal plasma during primary HIV infection.

Stekler J, Sycks BJ, Holte S, Maenza J, Stevens CE, Dragavon J, Collier AC, Coombs RW.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1269-74. doi: 10.1089/aid.2008.0014.

5.

Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections.

Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB.

Nat Med. 2008 Oct;14(10):1077-87. doi: 10.1038/nm.1871. Epub 2008 Sep 14.

PMID:
18806803
6.

Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression.

Soriano-Sarabia N, Vallejo A, Ramírez-Lorca R, Rodríguez Mdel M, Salinas A, Pulido I, Sáez ME, Leal M.

J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):128-35. doi: 10.1097/QAI.0b013e318184fb41.

PMID:
18769358
7.

Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis.

Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, Kajikawa O, Ruzinski JT, Rona G, Black RA, Stratton S, Jarvik GP, Hajjar AM, Nickerson DA, Rieder M, Sevransky J, Maloney JP, Moss M, Martin G, Shanholtz C, Garcia JG, Gao L, Brower R, Barnes KC, Walley KR, Russell JA, Martin TR.

Am J Respir Crit Care Med. 2008 Oct 1;178(7):710-20. doi: 10.1164/rccm.200803-462OC. Epub 2008 Jul 17.

8.

A functional toll-like receptor 8 variant is associated with HIV disease restriction.

Oh DY, Taube S, Hamouda O, Kücherer C, Poggensee G, Jessen H, Eckert JK, Neumann K, Storek A, Pouliot M, Borgeat P, Oh N, Schreier E, Pruss A, Hattermann K, Schumann RR.

J Infect Dis. 2008 Sep 1;198(5):701-9. doi: 10.1086/590431.

PMID:
18605904
9.

Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection.

Jiang W, Lederman MM, Mohner RJ, Rodriguez B, Nedrich TM, Harding CV, Sieg SF.

J Virol. 2008 Aug;82(16):7837-45. doi: 10.1128/JVI.00660-08. Epub 2008 Jun 4.

10.

Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis.

Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM.

PLoS One. 2008 Apr 2;3(4):e1915. doi: 10.1371/journal.pone.0001915.

11.

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD.

J Infect Dis. 2008 Feb 15;197(4):563-71. doi: 10.1086/526786.

PMID:
18275276
12.

Functional consequences of toll-like receptor 4 polymorphisms.

Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW, Netea MG.

Mol Med. 2008 May-Jun;14(5-6):346-52. doi: 10.2119/2007-00135.Ferwerda. Review.

13.

Toll-like receptor polymorphisms and susceptibility to human disease.

Misch EA, Hawn TR.

Clin Sci (Lond). 2008 Mar;114(5):347-60. doi: 10.1042/CS20070214. Review.

PMID:
18230059
14.

Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.

Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, Baker B, Zhu B, Le Gall S, Waring MT, Ahern R, Moss K, Kelleher AD, Coffin JM, Freeman GJ, Rosenberg ES, Walker BD.

Nat Immunol. 2007 Nov;8(11):1246-54. Epub 2007 Sep 30.

PMID:
17906628
15.

Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children.

Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Sztein MB, Boukhvalova MS, Hemming VG, Blanco JC, Vogel SN.

J Immunol. 2007 Sep 1;179(5):3171-7.

16.

Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection.

Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, Miedema F, Kootstra N, Schuitemaker H.

J Immunol. 2007 Sep 1;179(5):3133-43.

17.

Innate immunogenetics: a tool for exploring new frontiers of host defence.

Bochud PY, Bochud M, Telenti A, Calandra T.

Lancet Infect Dis. 2007 Aug;7(8):531-42. Review.

PMID:
17646026
18.

MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection.

Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG.

J Exp Med. 2007 Aug 6;204(8):1891-900. Epub 2007 Jul 16.

19.

TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide.

Tulic MK, Hurrelbrink RJ, Prêle CM, Laing IA, Upham JW, Le Souef P, Sly PD, Holt PG.

J Immunol. 2007 Jul 1;179(1):132-40.

20.

The toll-like receptor 4 Asp299Gly variant and tuberculosis susceptibility in HIV-infected patients in Tanzania.

Ferwerda B, Kibiki GS, Netea MG, Dolmans WM, van der Ven AJ.

AIDS. 2007 Jun 19;21(10):1375-7.

PMID:
17545720

Supplemental Content

Support Center